Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer.
This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer.
1. Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page i 4. Table of Contents - p. Page iv 5. Copyright - p. Page v 6. Cover Image Insert - p. Page vi 7. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. Page vii 8. About the Series Editor - p. Page vii 9. Aims and Scope of the Volume - p. Page ix 10. About the Volume Editor - p. Page x 11. Preface - p. Page xi 12. Contributors - p. Page xii 13. List of Illustrations - p. Page xiii 14. List of Tables - p. Page xiv 15. Chapter 1 : Historical development of EGFR-targeted therapy - p. Page xiv 16. Chapter 2 : The development and implementation of EGFR inhibitors in advanced NSCLC - p. Page 7 17. Chapter 3 : YAP/TAZ-mediated resistance to EGFR inhibitors - p. Page 30 18. Chapter 4 : Role of epithelial to mesenchymal transition in the resistant mechanism of EGFR-TKIs - p. Page 47 19. Chapter 5 : Apoptosis signaling in EGFR inhibitor resistance in NSCLC - p. Page 67 20. Chapter 6 : Control of EGFR signaling by endocytosis and endosomal trafficking - p. Page 83 21. Chapter 7 : Epithelial-mesenchymal transition and resistance to EGFR inhibitors - p. Page 100 22. Index - p. Page 117
Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer.
This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer.
1. Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page i 4. Table of Contents - p. Page iv 5. Copyright - p. Page v 6. Cover Image Insert - p. Page vi 7. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. Page vii 8. About the Series Editor - p. Page vii 9. Aims and Scope of the Volume - p. Page ix 10. About the Volume Editor - p. Page x 11. Preface - p. Page xi 12. Contributors - p. Page xii 13. List of Illustrations - p. Page xiii 14. List of Tables - p. Page xiv 15. Chapter 1 : Historical development of EGFR-targeted therapy - p. Page xiv 16. Chapter 2 : The development and implementation of EGFR inhibitors in advanced NSCLC - p. Page 7 17. Chapter 3 : YAP/TAZ-mediated resistance to EGFR inhibitors - p. Page 30 18. Chapter 4 : Role of epithelial to mesenchymal transition in the resistant mechanism of EGFR-TKIs - p. Page 47 19. Chapter 5 : Apoptosis signaling in EGFR inhibitor resistance in NSCLC - p. Page 67 20. Chapter 6 : Control of EGFR signaling by endocytosis and endosomal trafficking - p. Page 83 21. Chapter 7 : Epithelial-mesenchymal transition and resistance to EGFR inhibitors - p. Page 100 22. Index - p. Page 117
